Potentiating tumor immunity using aptamer-targeted RNAi to render CD8+ T cells resistant to TGFβ inhibition
TGFβ secreted by tumor cells and/or tumor infiltrating stromal cells is a key mediator of tumor growth and immune suppression at the tumor site. Nonetheless, clinical trials in cancer patients targeting the TGFβ pathway exhibited at best a modest therapeutic benefit. A likely reason, a common limita...
Main Authors: | Yvonne Puplampu-Dove, Tal Gefen, Anugraha Rajagopalan, Darija Muheramagic, Brett Schrand, Eli Gilboa |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2018-04-01
|
Series: | OncoImmunology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/2162402X.2017.1349588 |
Similar Items
-
Thermal Stability of siRNA Modulates Aptamer- conjugated siRNA Inhibition
by: Alexey Berezhnoy, et al.
Published: (2012-01-01) -
The use of oligonucleotide aptamers in cancer therapy
by: Adrian Odrzywolski, et al.
Published: (2016-05-01) -
Current progress of RNA aptamer-based therapeutics
by: Jiehua eZhou, et al.
Published: (2012-11-01) -
Methods for Evaluating Cell-Specific, Cell-Internalizing RNA Aptamers
by: James O. McNamara, et al.
Published: (2013-03-01) -
STAT3 Gene Silencing by Aptamer-siRNA Chimera as Selective Therapeutic for Glioblastoma
by: Carla Lucia Esposito, et al.
Published: (2018-03-01)